FDA
-
-
-
-
-
-
-
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
-
-
-
-
-
-
-
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
-
-
-
-
-
-
-
MediWound publishes phase II data linking wound preparation to healing
-
-
-
-
-
-
-
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
-
-
-
-
-
-
-
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
-
-
-
-
-
-
-
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
-
-
-
-
-
-
-
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

